Afficher la notice abrégée

Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorALLOUCHERY, Marion
dc.contributor.authorBRUNET, Kevin
dc.contributor.authorTOMOWIAK, Cecile
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSINGIER, Allison
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPAMBRUN, Elodie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
dc.contributor.authorPERAULT-POCHAT, Marie-Christine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
dc.date.accessioned2024-01-09T09:29:28Z
dc.date.available2024-01-09T09:29:28Z
dc.date.issued2023-11-20
dc.identifier.issn0933-7407en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186970
dc.description.abstractEnBACKGROUND: Data on the risk of invasive fungal infections (IFI) with ibrutinib treatment are scarce. OBJECTIVES: This study aimed to determine IFI incidence and risk factors in ibrutinib-treated patients in real-life settings. METHODS: We constituted a cohort of ibrutinib incident users in the French National Healthcare Database. All patients ≥18 years with a first dispensing of ibrutinib between 21 November 2014 and 31 December 2019 were included. Patients were followed from the cohort entry date until IFI, ibrutinib discontinuation, death, or 31 December 2020, whichever came first. The cumulative incidence function method was used to estimate the probability of IFI accounting for competing risk of death. A multivariate cause-specific Cox proportional hazards model was used to assess independent IFI risk factors. RESULTS: Among 6937 ibrutinib-treated patients, 1-year IFI cumulative incidence was 1.3%, with invasive aspergillosis being the most frequent. Allogenic or autologous stem cell transplantation (ASCT) (hazard ratio [HR] 3.59, 95% confidence interval [1.74; 7.41]), previous anticancer treatment (HR 2.12, CI 95% [1.34; 3.35]) and chronic respiratory disease (HR 1.66, [1.03; 2.67]) were associated with higher risk of IFI. Besides neutropenia and corticosteroids, use of anti-CD20 agents was significantly more frequent in patients having experienced IFI (HR 3.68, [1.82; 7.45]). CONCLUSIONS: In addition to patients with ASCT history, severe neutropenia or treated with corticosteroids, our findings support active surveillance of IFIs in those with chronic respiratory disease, previously treated, or treated with anti-CD20 agents in combination with ibrutinib. Further studies are needed to optimise IFI prophylaxis in these patient subgroups.
dc.language.isoENen_US
dc.title.enInvasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study
dc.title.alternativeMycosesen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/myc.13676en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37984556en_US
bordeaux.journalMycosesen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04381616
hal.version1
hal.date.transferred2024-01-09T09:29:30Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Mycoses&rft.date=2023-11-20&rft.eissn=0933-7407&rft.issn=0933-7407&rft.au=ALLOUCHERY,%20Marion&BRUNET,%20Kevin&TOMOWIAK,%20Cecile&SINGIER,%20Allison&PAMBRUN,%20Elodie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée